---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-006779"
form_type: "8-K"
ticker: "JANX"
cik: "0001817713"
company_name: "Janux Therapeutics, Inc."
filed_at: "2022-05-02T23:59:59+00:00"
generated_at: "2026-06-26T02:10:44.052015+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Janux presents preclinical data for JANX007 and JANX008 at PEGS Boston conference

## Summary
- Management presented two posters at PEGS Boston on May 2-5, 2022.
- JANX007 is a PSMA-targeted TRACTr for prostate cancer; JANX008 is EGFR-targeted for solid tumors.
- Data is preclinical; no clinical results or financial guidance disclosed.

## SEC filing metadata
- accession: 0000950170-22-006779
- form_type: 8-K
- ticker: JANX
- cik: 0001817713
- company_name: Janux Therapeutics, Inc.
- filed_at: 2022-05-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817713/000095017022006779/0000950170-22-006779-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817713/000095017022006779/janx-20220502.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-006779
- JSON: https://secwatch.observer/filing/0000950170-22-006779.json
- Plain text: https://secwatch.observer/filing/0000950170-22-006779.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.